TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Rapamycin
PubChem CID 5284616
Molecular Weight 914.2g/mol
Synonyms

(-)-Rapamycin, 53123-88-9, AY 22989, AY-22989, I 2190A, I-2190A, I2190A, NSC 226080, RAPA, Rapammune, Rapamune, Rapamycin, SIIA 9268A, Sirolimus, Wy 090217, rapalimus, Supralimus, WY-090217, Rapamycin (Sirolimus), HYFTOR, sirolimusum, Cypher, Antibiotic AY 22989, Rapamycin (GMP), FYARRO, CCRIS 9024, CHEBI:9168, SILA 9268A, W36ZG6FT64, HSDB 7284, L04AA10, Npc-12g, Rapamycin (GMP Like), SM-88 COMPONENT SIROLIMUS, DE-109, NSC-226080, UNII-W36ZG6FT64, DTXSID5023582, MFCD00867594, Rapamycin Immunosuppressant Drug, NAB-RAPAMYCIN COMPONENT RAPAMYCIN, Rapamycin (>85%), SIROLIMUS (MART.), SIROLIMUS [MART.], EC 610-965-5, SIROLIMUS (USP-RS), SIROLIMUS [USP-RS], NSC226080, (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, EVEROLIMUS IMPURITY A (EP IMPURITY), EVEROLIMUS IMPURITY A [EP IMPURITY], (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, DTXCID503582, Perceiva, 1fkb, 1pbk, NCGC00021305-05, Rapamycin/Sirolimus, LCP-Siro, (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((2S)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-((2R)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido(2,1-c)(1,4)oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-(methyloxy)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-10,21-bis(methyloxy)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone, RAP, RPM, S1039, SIROLIMUS [INN], SIROLIMUS [JAN], RAPAMYCIN [MI], Human Blood - Sirolimus, SIROLIMUS [HSDB], SIROLIMUS [USAN], SIROLIMUS [VANDF], BiomolKI2_000084, SCHEMBL3463, SIROLIMUS [WHO-DD], Rapamycin,Sirolimus,Rapamune, BIDD:PXR0165, SIROLIMUS [EMA EPAR], 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, MLS006010168, Sirolimus [USAN:INN:BAN], GTPL6031, SIROLIMUS [ORANGE BOOK], BDBM36609, MS-R001, S01XA23, HMS2089A21, HMS3403F11, HMS3884C03, HY-10219GL, EX-A1044, AC-722, BDBM50064359, HY-10219G, STL570275, AKOS015850976, AKOS015961618, CCG-100684, CS-0063, DB00877, NCGC00021305-06, NCGC00021305-07, Rapamycin from Streptomyces hygroscopicus, AS-11687, HY-10219, SMR004701276, Fyarro (sirolimus albumin-bound particles), UNM-0000358684, A-275, CS-0626126, CS-1010374, R0097, Rapamycin, VETRANAL(TM), analytical standard, M02444, Q32089, Q-201659, BRD-K84937637-001-04-0, BRD-K84937637-001-06-5, BRD-K89626439-001-01-0, Z2568665260, 24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypy, Rapamycin from Streptomyces hygroscopicus, >=95% (HPLC), powder, Rapamycin from Streptomyces hygroscopicus, Vetec(TM) reagent grade, >=95%, (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone, (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone, (3 S ,6 R ,7 E ,9 R ,10 R ,12 R ,14 S ,15 E ,17 E , 19 E ,21 S ,23 S ,26 R ,27 R ,34a S )-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34, 34a-hexadecahydro-9,27-dihydroxy-3-, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34 aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hex adecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydro xy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy- 6,8,12,14,20,26-hexamethyl-23,27-ep, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-223,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-ep, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-(methyloxy)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-10,21-bis(methyloxy)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,, 1,18-Dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-ethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.0*4,9*]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (Rapamycin), 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2
Drug Type Small molecule
Formula C₅₁H₇₉NO₁₃
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC
InChI 1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
InChIKey QFJCIRLUMZQUOT-HPLJOQBZSA-N
CAS Number 53123-88-9
ChEMBL ID CHEMBL413
ChEBI ID CHEBI:9168
TTD ID D05VYY
Drug Bank ID DB00877
Toxicity Organism Test Type Route(Dose)
rat LD50 intraperitoneal(165 mg/kg)
mouse LD50 intraperitoneal(254 mg/kg)
rat LD50 oral(322 mg/kg)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 378
Ref_1
Pair Name Resveratrol, Rapamycin
Partner Name Resveratrol
Disease Info [ICD-11: 2D10.1] Papillary thyroid cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL-xL hsa598
Up-regulation Expression CASP3 hsa836
Up-regulation Expression CASP8 hsa841
Up-regulation Expression CASP9 hsa842
Down-regulation Expression MCL1 hsa4170
Down-regulation Phosphorylation RPS6KB1 hsa6198
In Vitro Model KTC-1 Poorly differentiated thyroid gland carcinoma Homo sapiens (Human) CVCL_6300
TPC-1 Thyroid gland papillary carcinoma Homo sapiens (Human) CVCL_6298
In Vivo Model KTC-1 and TPC-1 cells in logarithmic growth phase were subcutaneously inoculated into the right armpit of nude mice (5×10⁶ cells/mouse).
Result The present study suggests that the combination of rapamycin and resveratrol may be a promising strategy for the treatment of papillary thyroid cancer.
Combination Pair ID: 765
Ref_2
Pair Name Honokiol, Rapamycin
Partner Name Honokiol
Disease Info [ICD-11: 2C90.0] Renal cell carcinoma Investigative
Biological Phenomena Induction-->ROS generation
Gene Regulation Down-regulation Expression CD274 hsa29126
In Vitro Model 786-O Renal cell carcinoma Homo sapiens (Human) CVCL_1051
ACHN Papillary renal cell carcinoma Homo sapiens (Human) CVCL_1067
Result Honokiol can effectively overcome the limitation of Rapamycin treatment alone; and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer.
Combination Pair ID: 2
Ref_3
Pair Name Camptothecin, Rapamycin
Partner Name Camptothecin
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Up-regulation Expression ATG5 hsa9474
Up-regulation Activity CASP9 hsa842
Up-regulation Expression MAP1LC3B hsa81631
In Vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens (Human) CVCL_0532
In Vivo Model Cells suspended in PBS were subcutaneously injected into the right back of mice.
Result Autophagy-induced intracellular signaling fractional nano-drug system for synergistic anti-tumor therapy
Combination Pair ID: 500
Ref_4
Pair Name Bisdemethoxycucurmin, Rapamycin
Partner Name Bisdemethoxycucurmin
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Inhibition-->Epithelial-mesenchymal transition
Gene Regulation Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP9 hsa842
Down-regulation Expression GPR161 hsa23432
Down-regulation Expression MMP9 hsa4318
Down-regulation Activity MTOR hsa2475
Down-regulation Activity RPS6KB1 hsa6198
Down-regulation Expression TWIST1 hsa7291
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
BT-549 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_1092
BT-20 Invasive breast carcinoma Homo sapiens (Human) CVCL_0178
Result Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelial-Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells.
Combination Pair ID: 710
Ref_5
Pair Name Beta-Elemene, Rapamycin
Partner Name Beta-Elemene
Disease Info [ICD-11: 2A83] Multiple myeloma Investigative
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
In Vitro Model FTC-133 Thyroid gland follicular carcinoma Homo sapiens (Human) CVCL_1219
Result We demonstrate that the novel combination of mTOR inhibitor with β-elemene synergistically attenuates tumor cell growth in follicular thyroid cancer, which requires additional preclinical validation.
03. Reference
No. Title Href
1 Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved. Arch Biochem Biophys. 2020 Aug 15;689:108461. doi: 10.1016/j.abb.2020.108461. Click
2 A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape. Cancers (Basel). 2020 Jul 3;12(7):1782. doi: 10.3390/cancers12071782. Click
3 Autophagy-induced intracellular signaling fractional nano-drug system for synergistic anti-tumor therapy. J Colloid Interface Sci. 2023 Sep;645:986-996. doi: 10.1016/j.jcis.2023.05.031. Click
4 Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelial-Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells. J Agric Food Chem. 2021 Dec 8;69(48):14557-14567. doi: 10.1021/acs.jafc.1c05585. Click
5 Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer Cells. Biomed Res Int. 2016;2016:6723807. doi: 10.1155/2016/6723807. Click
It has been 26242 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP